40 likes | 64 Views
Botulinum toxin is a product produced by naturally occurring Clostridium botulinum bacteria. This bacteria is found in soil and marine sediments and can produce harmful neurotoxin botulinum toxin.<br>
E N D
Botulinum Toxin Market - Global Industry Botulinum Toxin Market - Global Industry Insights, and Forecast till 2026 Insights, and Forecast till 2026 Botulinum toxin is a product produced by naturally occurring Clostridium botulinum bacteria. This bacteria is found in soil and marine sediments and can produce harmful neurotoxin botulinum toxin. Botulinum toxin is a ‘blocking agent’ which inhibits the release of certain neurotransmitters, specifically acetylcholine, from the endings of the motor nerves. There are about eight types of botulinum toxin named from type A to H. Botulinum toxin type A and botulinum toxin type B are majorly used in cosmetic procedures for the treatment of various facial conditions, its commercially marketed under the brand name Botox. Botulinum toxin type A and B are also used in medical applications for treatment of various diseases such as dystonia, chronic migraines, and spasticity. Get Sample Copy At: Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1518 https://www.coherentmarketinsights.com/insight/request-sample/1518 Botulinum Toxin Market: Drivers Botulinum Toxin Market: Drivers Frequent approvals of novel botulinum toxin products for different indications are expected to drive growth of the Botulinum Toxin Market in near future. For instance, in 2016, Ipsen S.A. received the U.S. Food and Drug Administration (FDA) approval for its Dysport (abobotulinumtoxinA) injection indicated for the treatment of pediatric lower limb (PLL) spasticity in children of age two years and older. In 2017, company received the FDA approval for same product to use in adults. In 2017, Allergan plc. received FDA approval for BOTOX Cosmetic (OnabotulinumtoxinA) for new indication in forehead lines, and previously the product has been approved for the treatment of , crow's feet lines, and glabellar lines. With this approval company has expanded the indication of its product in the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. In 2014, Allergan Inc. received approval for its BOTOX (Botulinum toxin type A) from Medicines and Healthcare Products Regulatory Agency (MHRA) in U.K. BOTOX was approved in the U.K. for treatment of ankle disability due to lower limb spasticity associated with stroke in adults. In 2016, Daewoong Pharmaceutical Co., Ltd received approval for its botulinum toxin Nabota in Mexico and India. Nabota was introduced by Daewoong Pharmaceutical Co., Ltd in South Korea in 2014. In 2015, Merz North America, the U.S. subsidiary of the global Merz Pharma Group, received U.S. FDA approval for Xeomin (incobotulinumtoxinA) indicated for the
treatment of upper limb spasticity (ULS) in adult patients. Furthermore, increasing trend of botulinum toxin in cosmetic procedures is also expected to increase the growth of Botulinum Toxin Market in near future. For instance, according to a report published by American Society of Plastic Surgeons in 2016, around 7,056,255 cosmetic minimally-invasive procedures were performed with Botulinum toxin Type A (Botox, Dysport, and Xeomin), there was an increase of 4% in procedures as compared to 2015. Increasing number of procedures with botulinum toxin along with increasing approved indication is expected to drive growth of the global Botulinum Toxin Market. Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Botulinum Toxin Market Research Objective and Assumption • Botulinum Toxin Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Botulinum Toxin Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Botulinum Toxin Market, By Regions • Botulinum Toxin Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Botulinum Toxin Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Botulinum Toxin Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Botulinum Toxin Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion
Botulinum Toxin Market: Regional analysis Botulinum Toxin Market: Regional analysis North America is expected to hold a dominant position in the global botulinum toxin market, owing to increasing trend of cosmetic procedures in the region. For instance, according to a report published by American Society of Plastic Surgeons in 2016, around US$ 16.4 billion was spent on cosmetic procedures in the U.S. and in 2017, around 7.2 million botulinum injections were used in the U.S. for cosmetic procedures. Increasing number of cosmetic procedures in the key region of North America is expected to drive the growth of the botulinum toxin market in near future. Furthermore, Asia Pacific is expected to show rapid growth in botulinum toxin market, owing to increasing R&D and approval of novel products in China. For instance, in January 2018, Daewoong Pharmaceutical Co. Ltd., a Korean company, received approval from the Chinese authorities to conduct clinical trials for botulinum toxin Nabota in China. Request For Customization of Research Report @ Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1518 https://www.coherentmarketinsights.com/insight/request-customization/1518 Botulinum Toxin Market: Key Players Botulinum Toxin Market: Key Players Key players operating in global botulinum toxin market includes Ipsen group, Allergan Plc., Medytox Inc., Merz GmbH and Co. KGaA, US Worldmed, LLC, Lanzhou Institute of Biological Products Co. Ltd., Revance Therapeutics, Inc., and Daewoong Pharmaceutical Co., Ltd. Major players in market are involved in strategic collaborations to develop new products. For instance, in February 2018, Mylan N.V. and Revance Therapeutics, Inc. underwent strategic collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA). Furthermore, key players are focusing on receiving approvals of its product in key market to expand their presence in global market. For instance, in February 2018, Medytox Inc. filed a new drug application with the China Food and Drug Administration (CFDA) to its botulinum neurotoxin product Meditoxin in China. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com